Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00412594 · ClinicalTrials.gov registry record · Phase 2

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

A Phase 2 study of Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT00412594 is a Phase 2 study of Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants, above the 63-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (138% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00412594, a Phase 2 study of Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.

Conditions Studied

Hairy Cell Leukemia Recurrent Hairy Cell Leukemia

Interventions

  • DRUG Cladribine
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Rituximab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2004-06-10
Est. Completion 2027-06-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00412594

The ClinicalTrials.gov registry entry for NCT00412594 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (138% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hairy Cell Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Cladribine is the first listed.

NCT00412594 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00412594 about?

NCT00412594 is a clinical study titled "Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia". This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing...

What is the current status of trial NCT00412594?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-06-10. Estimated completion is 2027-06-30.

What conditions does trial NCT00412594 study?

This clinical trial studies the following conditions: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia.

What interventions are being tested in trial NCT00412594?

The interventions under investigation include: Cladribine (DRUG), Laboratory Biomarker Analysis (OTHER), Rituximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00412594?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00412594 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hairy Cell Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hairy Cell Leukemia

All registered trials for this condition

Recurrent Hairy Cell Leukemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.